Iroquois Capital Management LLC, Richard Abbe, and Kimberly Page filed Amendment No. 6 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of Common Shares of Clearmind Medicine Inc. as of September 30, 2026.
Key Highlights
- Three reporting persons: Iroquois Capital Management LLC, Richard Abbe, and Kimberly Page are collectively identified as the reporting persons in this filing.
- Warrant-only holdings: All reported beneficial ownership consists of Common Shares issuable upon exercise of warrants; Iroquois Master Fund held 0 Common Shares directly, and ICIG held 0 Common Shares directly, as of the event date.
- Iroquois Master Fund warrants: Iroquois Master Fund held Reported Warrants to purchase 335,000 Common Shares as of September 30, 2026.
- ICIG warrants: Iroquois Capital Investment Group LLC (ICIG) held Reported Warrants to purchase 315,000 Common Shares as of September 30, 2026.
- Ownership percentage: Each reporting person's beneficial ownership is listed at 9.99% of the class, after giving effect to ownership blockers, based on 2,145,211 Common Shares outstanding as of July 31, 2026.
- Blocker provisions: According to the filing, the Reported Warrants cannot be exercised to the extent the reporting persons would beneficially own more than 9.99% of outstanding Common Shares, with certain warrants subject to a 4.99% blocker instead.
Iroquois Group Discloses Warrant Position in Clearmind Medicine
The Schedule 13G Amendment No. 6 covers Common Shares of Clearmind Medicine Inc. (CUSIP 185053600), a company whose principal executive offices are located at 101-1220 West 6th Avenue, Vancouver, British Columbia V6H1A5. The filing was triggered by an event dated September 30, 2026, and was submitted by three reporting persons sharing the principal business address of 2 Overhill Road, Scarsdale, NY 10583.
According to the filing, Iroquois Capital Management LLC is the investment adviser for Iroquois Master Fund Ltd., and Richard Abbe serves as President of Iroquois Capital and also has sole authority over investments made on behalf of ICIG. Richard Abbe and Kimberly Page are each identified as directors of Iroquois Master Fund and share authority and responsibility for its investments. As a result, the filing states, Mr. Abbe may be deemed the beneficial owner of Common Shares held by both Iroquois Master Fund and ICIG, while Ms. Page may be deemed beneficial owner of shares held by Iroquois Master Fund. The filing notes that "the foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of Common Shares owned by another Reporting Person."
The percentage figures in the filing are based on 2,145,211 Common Shares outstanding as of July 31, 2026, as represented in the company's Report of Foreign Private Issuer on Form 6-K filed with the SEC on September 10, 2026. Richard Abbe's aggregate beneficial ownership is reported as 650,000 Common Shares (all warrant-derived), while Iroquois Capital Management LLC and Kimberly Page each report 335,000 Common Shares on the same basis. The filing states that the securities reported were not acquired and are not held for the purpose of changing or influencing control of the issuer.
What Was Disclosed
Iroquois Capital Management LLC, Richard Abbe, and Kimberly Page filed Amendment No. 6 to Schedule 13G disclosing warrant-based beneficial ownership in Clearmind Medicine Inc., with all positions subject to 9.99% and 4.99% exercise blockers as of September 30, 2026.




Please wait processing your request...